Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 593-601 , November 2011

Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer

  • Heather Payne, F.R.C.P.

      Affiliations

    • Department of Oncology, UCLH NHS Foundation Trust, London, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44(0)207 380 9150; fax: +44 (0)207 224 5706
    • ,
  • Philip Cornford, M.D.

      Affiliations

    • Department of Urology, The Royal Liverpool University Hospital, Liverpool, United Kingdom

Received 1 October 2009 ,Revised 29 October 2009 ,Accepted 4 November 2009.

References 

  1. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection, and monitoring. Nat Rev Cancer. 2008;8:268–278
  2. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985;76:1899–1903
  3. Pienta KJ. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. Urology. 2009;73:S11–S20
  4. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen (1979 [classical article]). J Urol. 2002;167:1226–1230
  5. Shah JB, Reese AC, McKiernan JM, et al. PSA updated: Still relevant in the new millennium?. Eur Urol. 2005;47:427–432
  6. Parekh N, Lin Y, Marcella S, et al. Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: Evidence from the National Health and Nutrition Examination Survey (2001–2004). Cancer Epidemiol Biomarkers Prev. 2008;17:2467–2472
  7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  8. McDavid K, Lee J, Fulton JP, et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep. 2004;119:174–186
  9. Wilson JM, Jungner YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968;65:281–393
  10. Makarov DV, Carter HB. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol. 2006;176:2383–2385
  11. Barry MJ. Screening for prostate cancer—the controversy that refuses to die. N Engl J Med. 2009;360:1351–1354
  12. Screening for prostate cancer (American College of Physicians). Ann Intern Med. 1997;126:480–484
  13. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers (Also: Update 2001—testing for early lung cancer detection). CA Cancer J Clin. 2001;51:38–75
  14. US Department of Health and Human Services. 2009;http://www.ahrq.gov/clinic/uspstf08/prostate/prostaters.htm
  15. National Health Services Screening Programmes. 2009;http://www.cancerscreening.nhs.uk/prostate/index.html
  16. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  17. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  18. American Cancer Society Guidelines for the Early Detection of Cancer. 2009;http://www.cancer.org/docroot/ped/content/ped_2_3x_acs_cancer_detection_guidelines_36.asp
  19. Carroll P, Albertsen PC, Greene K. Prostate specific antigen: Best practice statement (2009 Update). http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf
  20. National comprehensive cancer network clinical practice guidelines in oncology; prostate cancer V. 2.2009. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf
  21. Lim LS, Sherin K. Screening for prostate cancer in US men ACPM position statement on preventive practice. Am J Prev Med. 2008;34:164–170
  22. Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: Early detection, treatment, outcome, incidence, and mortality. BJU Int. 2008;101:809–816
  23. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311–318
  24. Lu-Yao G, Albertsen PC, Stanford JL, et al. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: 15-year Follow-up. J Gen Intern Med. 2008;23:1809–1814
  25. Lin K, Lipsitz R, Miller T, et al. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the US Preventive Services Task Force. Ann Intern Med. 2008;149:192–199
  26. Schopper D, de Wolf C. How effective are breast cancer screening programmes by mammography? (Review of the current evidence). Eur J Cancer. 2009;45:1916–1923
  27. Njor SH, Olsen AH, Schwartz W, et al. Predicting the risk of a false-positive test for women following a mammography screening program. J Med Screen. 2007;14:94–97
  28. Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1–88
  29. Freedland SJ, Hotaling JM, Fitzsimons NJ, et al. PSA in the new millennium: A powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes—results from the SEARCH database. Eur Urol. 2008;53:758–764
  30. Chun FK, Briganti A, Gallina A, et al. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol. 2007;52:1067–1074
  31. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439
  32. D'Amico AV, Moul J, Carroll PR, et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172:S42–S46
  33. Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the post-treatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: A multi-institutional pooled analysis. Cancer. 2006;107:1496–1502
  34. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  35. Ryan CJ, Smith A, Lal P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression. Urology. 2006;68:834–839
  36. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res. 2004;64:9209–9216
  37. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989;8:431–440
  38. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376–1383
  39. Mulders PF, Schalken JA. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2009;12:241–246
  40. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965–3970
  41. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  42. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  43. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators. J Clin Oncol. 2007;25:669–674
  44. Collette L. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol. 2008;53:6–9
  45. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679–689
  46. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959–1966
  47. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113:2478–2487
  48. Dawson NA. Targeted therapy in prostate cancer—are we our own worst enemy?. Cancer. 2008;113:2376–2378
  49. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomized, phase II trial. Eur Urol. 2009;55:1112–1123
  50. Fizazi K, Miller K. Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer. BJU International. 2009;104:1423–1425
  51. Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 2009;103:1636–1640
  52. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–1159
  53. Ning YM, Gulley J, Arlen P, et al. An exploratory analysis of the association between PSA Working Group I (PSAWG) progression and clinical progression (radiographic or symptomatic) in patients with metastatic castration-refractory prostate cancer (mCRPC) treated with a docetaxel-based regimen. Proceedings of the Genitourinary Cancers Symposium (ASCO), Orlando (FL), February 2009; [Abstract 192].
  54. Botchorishvili G, Matikainen MP, Lilja H. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol. 2009;19:221–226
  55. Lin DW. Beyond PSA: Utility of novel tumor markers in the setting of elevated PSA. Urol Oncol. 2009;27:315–321
  56. Makarov DV, Loeb S, Getzenberg RH, et al. Biomarkers for Prostate Cancer. Annu Rev Med. 2009;60:139–151
  57. Okegawa T, Nutahara K, Higashihara E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol. 2009;181:1091–1097
  58. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–6309
  59. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100:671–675
  60. Getzenberg RH, Pienta KJ, Huang EY, et al. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res. 1991;51:6514–6520
  61. Dhir R, Vietmeier B, Arlotti J, et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol. 2004;171:1419–1423
  62. Leman ES, Cannon GW, Trock BJ, et al. EPCA-2: A highly specific serum marker for prostate cancer. Urology. 2007;69:714–720
  63. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res. 2002;62:2220–2226
  64. Rubin MA, Zhou M, Dhanasekaran SM, et al. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287:1662–1670
  65. Zielie PJ, Mobley JA, Ebb RG, et al. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. J Urol. 2004;172:1130–1133
  66. Ouyang B, Bracken B, Burke B, et al. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol. 2009;181:2508–2513
  67. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089–1095
  68. van Gils MP, Hessels D, van HO, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination: A Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13:939–943
  69. Ryan A, Wilson S, Greenfield S, et al. Range of self-tests available to buy in the United Kingdom: An Internet survey. J Public Health (Oxf). 2006;28:370–374
  70. Cancer Research UK. The PCA3 test for prostate cancer. 2009;http://www.cancerhelp.org.uk/about-cancer/cancer-questions/the-pca3-test-for-prostate-cancer
  71. Veridex LLC UK Price List. 2009;

PII: S1078-1439(09)00356-1

doi: 10.1016/j.urolonc.2009.11.003

Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 593-601 , November 2011

Article Tools